Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Inclusion Criteria: * Patient with pancreatic, duodenal, or small intestine fistula * Patient with simple, externalised fistula * Patient with fistula for which a medical conservative treatment is considered * Patient with: * for pancreatic fistulae: a mean drainage volume more than or equal to 100 ml/24h over 48 hours or more than or equal to 50 ml / 24h over 3 days and a concentration of amylase in the drainage fluid 3 times higher than in the serum over at least 2 or 3 consecutive days respectively, * for duodenal and small intestine fistulae: a mean drainage volume more than or equal to 100ml/24h over 2 days Exclusion Criteria: * Patient expected to require a surgical treatment of the fistula during the study * Patient having uncontrolled intra-abdominal sepsis; Crohn's disease; radiotherapy lesions of the small bowel; a mesenteric vascular insufficiency; a fistula localised in cancer-infiltrated areas; a distal obstruction; an exposed fistula of the small intestine; or intra-abdominal foreign bodies. * Patient receiving long-term corticotherapy * Patient having received any somatostatin analogue as curative treatment of the fistula or any PRF somatostatin analogue within the previous month. * Patient having previously undergone a transplant